NSG
CALT

Nalls Sherbakoff Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Nalls Sherbakoff Group’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$464 Sell
18
-17
-49% -$318 ﹤0.01% 419
2023
Q3 		$640 Hold
35
– – ﹤0.01% 423
2023
Q2 		$594 Hold
35
– – ﹤0.01% 443
2023
Q1 		$808 Buy
+35
New +$699 ﹤0.01% 456

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nalls Sherbakoff Group's CALT Position: Q4 2023 in Review

Nalls Sherbakoff Group reduced its Calliditas Therapeutics AB American Depositary Shares (CALT) stake by 49% in Q4 2023, selling an estimated $318 and leaving 18 shares worth $464. The position accounts for ﹤0.01% of the portfolio, ranked #419.

Nalls Sherbakoff Group first reported a position in CALT in Q1 2023 and has held it in 4 quarters since. The position peaked at $808 in Q1 2023. 21 funds tracked by Wall St. Rank hold CALT as of Q4 2023.

  • Nalls Sherbakoff Group held 18 shares of Calliditas Therapeutics AB American Depositary Shares worth $464 as of Q4 2023.
  • Nalls Sherbakoff Group sold 17 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2023, an estimated $318.
  • Calliditas Therapeutics AB American Depositary Shares made up ﹤0.01% of Nalls Sherbakoff Group's portfolio in Q4 2023, its #419 holding.
  • Nalls Sherbakoff Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q1 2023 and has held it in 4 quarters since.
  • Nalls Sherbakoff Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $808 in Q1 2023.
  • 21 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2023.

Based on Nalls Sherbakoff Group's 13F filing for Q4 2023, filed 9 Apr 2024.